Spravato / Ketamine For Depression: Decoding Their Mechanism of Action
Spravato (esketamine) and ketamine both work in the same way. They work primarily by modulating the brain's glutamate system – the primary excitatory neurotransmitter network in the central nervous system. Unlike traditional antidepressants that target serotonin, norepinephrine, and/or dopamine, esketamine blocks NMDA receptors on glutamate neurons, triggering a rapid downstream cascade that increases brain-derived neurotrophic factor (BDNF) and promotes the formation of new synaptic connections. This is the neurobiological basis for Spravato's FDA-approved use in adults with treatment-resistant depression and major depression with suicidal thoughts.
But stating the mechanism in a single paragraph barely scratches the surface of what is actually happening at the circuit level – and why that distinction matters if you have tried multiple medications without meaningful relief. What follows is a deeper, clinically grounded exploration of the Spravato mechanism of action, why glutamate matters more than you might realize, and how this treatment creates what our team describes as a biologically receptive window for change.
Why Glutamate – and Why It Changes Everything
For decades, the dominant theory of depression centered on monoamine neurotransmitters – serotonin, norepinephrine, and dopamine. SSRIs, and SNRIs, NDRIs, NASAs, etc. were designed around this framework, and they remain useful tools for many people. But they may fail to produce an adequate response for roughly 30 to 40 percent of individuals navigating major depressive disorder. This clinical reality forced researchers to look beyond the monoamine hypothesis entirely.
Glutamate offered an answer. It is the brain's most abundant excitatory neurotransmitter, involved in virtually every higher-order cognitive process – learning, memory consolidation, emotional regulation, and the ability to form new thought patterns. When depression becomes entrenched, glutamate signaling doesn't simply decrease, it becomes dysregulated. Synapses atrophy. Neural circuits that govern mood, motivation, and self-perception lose their flexibility.
This is where Spravato enters the picture. Esketamine – the S-enantiomer of the ketamine molecule (the "S" stands for sinistrum, Latin for "left," as the esketamine molecule is oriented to the left) – is the more active component of the broader ketamine compound. By selectively blocking NMDA receptors, it initiates what neuroscientists describe as a "glutamate surge." This surge activates AMPA receptors, which in turn stimulate the release of BDNF, a protein essential for synaptic growth and repair.
In practical terms, this means Spravato doesn't just alter the chemical balance in your brain. It aims to help your brain rebuild the physical connections that depression has eroded.
The BDNF Cascade: From Receptor Blockade to Synaptic Repair
Understanding the Spravato mechanism of action requires following the chain reaction that begins at the NMDA receptor and ends at the synapse. Here is the sequence as current evidence describes it:
- NMDA receptor blockade: Esketamine binds to and blocks NMDA receptors, particularly on GABAergic interneurons, temporarily disinhibiting glutamate release
- Glutamate surge: The resulting burst of glutamate activates AMPA receptors on postsynaptic neurons
- mTOR pathway activation: AMPA receptor stimulation triggers intracellular signaling cascades, including the mechanistic target of rapamycin (mTOR) pathway
- BDNF upregulation: mTOR activation increases the production and release of brain-derived neurotrophic factor
- Synaptogenesis: BDNF promotes the growth of new dendritic spines and synaptic connections – a process called synaptogenesis, essentially the structural rebuilding of neural circuits
This entire cascade can begin within hours, which explains why you might experience meaningful shifts in mood far more rapidly than with conventional antidepressants. A landmark study published in the New England Journal of Medicine demonstrated statistically significant improvement in depressive symptoms within 24 hours of esketamine administration for adults with treatment-resistant depression – a timeline that would be essentially impossible through serotonergic mechanisms alone.
What Makes Esketamine Different from Racemic Ketamine at the Molecular Level
This is a distinction that matters clinically. When we discuss ketamine therapy at Lumin Health, we are precise about which molecule we are referring to – because the pharmacology is meaningfully different.
Esketamine is the isolated S-enantiomer. This isolation is the primary reason the FDA pathway focused on the S-enantiomer for its nasal spray formulation.
Racemic ketamine – utilized in an evidence-based, off-label application of a medicine that’s been in use in the world of anesthesia for over 50 years – is a racemic mixture containing both the S-ketamine (left oriented) and R-ketamine (right oriented) molecules in equal proportion. Emerging preclinical research suggests R-ketamine may have its own distinct antidepressant properties, potentially mediated through different pathways including AMPA receptor activation and anti-inflammatory mechanisms. The clinical significance of this is still being studied.
Side effect profiles between esketamine and ketamine are the same. What differs is the regulatory pathway, the route of administration, and the clinical infrastructure around delivery. Spravato is administered as a nasal spray in a certified healthcare setting under direct observation. Ketamine treatment through Lumin Health is provided as intramuscular (IM) injections, which you may find offers distinct benefits in terms of speed and comfort compared to a slow IV infusion.
"When I explain Spravato's mechanism of action to you, I focus first on human element, because your brain isn't broken – it may be stuck. The glutamate surge that esketamine triggers doesn't resolve anything in isolation. It creates a window – a biologically receptive period – where your own capacity for change, your own intent, becomes the active ingredient. The medication prepares the soil. You do the growing." – Dr. Ben Yudkoff, Chief Medical Officer at Lumin Health
The Default Mode Network: Where Mechanism of Action Meets Lived Experience
The molecular cascade described above – NMDA blockade, glutamate surge, BDNF release, synaptogenesis – tells us what is happening at the cellular level. But the question you likely care about is: what does this mean for the way you think and feel?
The answer lives in the brain's large-scale networks, particularly what neuroscientists call the Default Mode Network (DMN) – the constellation of brain regions most active when you are not focused on external tasks. The DMN governs self-referential thought: your internal monologue, your sense of identity, your autobiographical narrative.
In depression, the DMN can become overactive and rigid, trapping you in cycles of rumination, hopelessness, and negative self-perception. Thought patterns and behavioral patterns, written in white matter tracks in other parts of the brain, become inflexible. Reward circuits are skewed. Futility and hopelessness are hard-coded into the system's default operating mode.
The Spravato mechanism of action is clinically significant precisely because it appears to modulate this rigidity. Functional neuroimaging studies suggest that ketamine-class compounds temporarily reduce hyperconnectivity within the DMN, creating a period of increased cognitive and emotional flexibility. During this window, patterns that felt immovable may become accessible to re-evaluation and change.
This is why self-guided intent matters so profoundly. The medication creates a neurobiological opening. But what you bring into that opening – your awareness, your behavioral support work, your willingness to engage differently with entrenched patterns – is what determines whether the opening leads to sustained relief.
The Mu-Opioid System: A Piece of the Puzzle That Often Gets Overlooked
Most discussions of Spravato and ketamine for depression stop at glutamate and BDNF. But the full mechanistic picture is more nuanced than that.
Esketamine also interacts with the brain's mu-opioid receptor system. This is not the same as saying it functions like a traditional opioid – the interaction is pharmacologically distinct. What appears to happen is that ketamine-class compounds sensitize the brain cell to endorphins, the body's naturally produced opioid peptides, that are responsible for producing the feeling associated with a runner’s high. Think of it as putting out more satellite dishes to pick up the signal – the endorphin signal your brain already generates but may have lost the ability to fully receive.
This mechanism may partially explain the rapid improvement in anhedonia – the inability to feel pleasure – that you may experience. It is analogous to the neurochemistry behind a "runner's high," where endorphin binding to mu-opioid receptors produces a natural sense of wellbeing and reward.
Understanding this layer of the mechanism is important for clinical transparency. If you have a history of substance dependence—opioid or other—you should speak with providers about where you are in recovery. It can help cue the provider into particular monitoring considerations and help us deliver care safely.
Why Speed of Onset Matters Clinically – Not Just Emotionally
The rapid onset of esketamine's antidepressant effects – sometimes within hours, often within days – is not merely a convenience. If you are exploring care for major depression with suicidal thoughts, the difference between a medication that takes 6 to 8 weeks to reach a therapeutic effect and one that may begin modulating mood within a single session is not academic. It is a vital clinical distinction.
This speed is a direct consequence of the mechanism of action. Serotonergic antidepressants require weeks of consistent receptor occupancy before downstream adaptations produce clinical improvement. Spravato's glutamate-driven pathway bypasses this delay entirely, initiating synaptogenesis and circuit-level changes on a fundamentally different timeline.
At Lumin Health, this is part of why our psychiatrist-led, academically-affiliated providers approach the initial evaluation process with such thoroughness. We are not simply determining whether you qualify for a specific path. We are assessing your full clinical picture – severity of symptoms, treatment history, medical comorbidities, substance use history – to determine whether the rapid-acting mechanism of Spravato or the distinct pharmacological profile of IM ketamine therapy is the more appropriate fit for you.
What the Research Shows: Efficacy Data in Context
Clinical data on Spravato's efficacy is robust but requires honest contextualization. Pivotal trials, including research published in JAMA Psychiatry, demonstrated statistically significant improvements in Montgomery–Åsberg Depression Rating Scale (MADRS) scores compared to placebo plus an oral antidepressant. Response rates in treatment-resistant populations have been reported in the range of 60 to 80 percent in open-label extension studies, with many achieving sustained improvement over months of maintenance dosing.
However, meaningful relief looks different for everyone, and not everyone experiences the same response. If you do respond, the degree of improvement varies considerably. Factors we observe clinically that appear to influence your outcomes include:
- The degree of support work you have in between sessions - both in terms of psychotherapy and family/friends
- Sleep quality and circadian rhythm stability
- Whether your treatment-resistant depression involves significant anxiety comorbidity
- Your own self-guided intent and engagement with the process
- Duration and severity of the current depressive episode
This is why ketamine treatment and Spravato should never be framed as standalone interventions. The mechanism of action creates a biological opportunity. Meaningful relief may be possible when that opportunity is paired with your own agency and commitment to change.
Insurance, Access, and the Practical Reality of Spravato Treatment
One of the most common questions we receive at Lumin Health relates not to the mechanism of action itself, but to how you can actually access the treatment. A few practical clarifications are worth noting:
Spravato is a REMS-certified medication, meaning it can only be administered at certified healthcare settings where you are monitored for a minimum of two hours post-dosing. This is not optional – it is a federal safety requirement. Vital signs are checked at regular intervals. A ride home is required.
Insurance coverage for Spravato typically requires documentation that you meet the criteria for treatment-resistant depression. Insurance companies add their own nuance to defining TRD – the commonly cited "failure of two adequate antidepressant trials" is a starting framework, not a universal truth. Navigating authorization often requires clinical expertise and familiarity with payer-specific requirements, which our team manages as part of the evaluation process.
Spravato can be delivered through what's called a "pharmacy benefit" model, where the medication is shipped directly for you, or through a "Buy and Bill" structure, where the practice maintains stock. Both have implications for copay structures, and our team walks you through the specifics during your initial evaluation.
Frequently Asked Questions About Spravato's Mechanism of Action
How is the Spravato mechanism of action different from an SSRI?
SSRIs increase serotonin availability in the synaptic cleft and require weeks of consistent use before downstream neuroadaptations produce clinical improvement. Spravato acts on an entirely different neurotransmitter system – glutamate – and initiates rapid synaptogenesis through BDNF release. The timeline and the biological pathway are fundamentally distinct, which is why esketamine can produce effects within hours rather than weeks.
Does Spravato permanently change brain chemistry?
No single treatment permanently alters brain chemistry. What Spravato aims to do is promote the growth of new synaptic connections and modulate rigid neural circuit patterns – paying special attention to networks like the DMN – creating a window of enhanced neuroplasticity (the brain's ability to reorganize and form new connections). Sustaining those changes typically requires ongoing behavioral support, continued treatment sessions as indicated, and your own engaged self-guided intent.
Is the dissociative experience part of how Spravato works?
Dissociation is a known side effect that you may experience during sessions. Whether dissociation is mechanistically required for antidepressant efficacy remains an open question in the research literature. Some studies suggest that the degree of dissociation does not correlate with treatment response, while others propose that the temporary disruption of rigid self-referential processing may contribute to the therapeutic effect or represent a ceiling dosage - meaning providing additional treatment beyond the dissociative window does not provide additional benefit. We monitor you throughout the experience and discuss what to expect before the first session.
Moving Forward: What Understanding the Mechanism Means for Your Decision
Knowing how Spravato works at the neurobiological level is more than an intellectual exercise. If you are exploring this treatment, understanding the mechanism provides something that months or years of trial-and-error with conventional antidepressants may not have: a coherent explanation for why previous treatments didn't provide relief and a biologically grounded reason to believe that a different approach may help.
Your brain is not broken – it may be stuck. The glutamate system, the BDNF cascade, the modulation of overactive default mode processing – these are not abstractions. They describe real, measurable changes that Spravato and ketamine treatment aim to initiate. But the medication disinhibits and sensitizes. It does not do the work for you. Your capacity, your intent, your willingness to engage with the window that treatment creates – these are the elements that transform a pharmacological mechanism into meaningful, sustained relief.
If you are exploring whether Spravato or ketamine therapy may be a fit for where you are right now, we would be grateful to walk with you towards relief. Lumin Health's academically-affiliated providers are available for an evaluation to determine what treatment path – if any – makes clinical sense for your situation.
